Cost-effectiveness analysis of lapatinib plus capecitabine versus capecitabine alone in the second line treatment for breast cancer treatment

被引：0
|
作者：
Ejzykowicz, F. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70201-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A60 / A61
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Passos, R. B. F.
    Teich, N.
    Canella, M.
    VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
  • [2] Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
    Bao, Yuwen
    Zhang, Zhuolin
    He, Xuan
    Cai, Lele
    Wang, Xiao
    Li, Xin
    CURRENT ONCOLOGY, 2022, 29 (09) : 6053 - 6067
  • [3] Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
    Wu, Yue
    Dong, Zhu
    Wang, Jiangfeng
    Fang, Qingxia
    BMJ OPEN, 2022, 12 (11):
  • [4] Cost-effectiveness of Capecitabine plus Irinotecan Versus Leucovorin plus Fluorouracil plus Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China
    Wu, Qiuji
    Zhang, Pengfei
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Li, Qiu
    CLINICAL THERAPEUTICS, 2020, 42 (11) : 2148 - +
  • [5] Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China
    Liao, Mengting
    Jiang, Qin
    Hu, Huabin
    Han, Jiaqi
    She, Longjiang
    Yao, Linli
    Ding, Dong
    Huang, Jin
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (06) : 584 - 592
  • [6] Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
    Peng, Jingyuan
    Tang, Chongqing
    Zeng, Xiaohui
    Liu, Shikun
    PLOS ONE, 2018, 13 (06):
  • [7] Lapatinib plus capecitabine in breast cancer - Reply
    Geyer, Charles E.
    Forster, John
    Cameron, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (14): : 1471 - 1472
  • [8] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    P.-F Zhang
    F. Wen
    J. Zhou
    J.-X. Huang
    K.-X. Zhou
    Q.-J. Wu
    X.-Y. Wang
    M.-X. Zhang
    W.-T. Liao
    Q. Li
    Clinical and Translational Oncology, 2020, 22 : 103 - 110
  • [9] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    Zhang, P. -F
    Wen, F.
    Zhou, J.
    Huang, J. -X.
    Zhou, K. -X.
    Wu, Q. -J.
    Wang, X. -Y.
    Zhang, M. -X.
    Liao, W. -T.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (01): : 103 - 110
  • [10] Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer
    Li, Lun
    Li, Jiang
    Yang, Kehu
    Tian, Jinhui
    Sun, Tiantian
    Jia, Wenqin
    Zhang, Peng
    Yi, Kang
    FUTURE ONCOLOGY, 2010, 6 (02) : 201 - 207
12345